Navigation Links
PTC Therapeutics Appoints Robert Spiegel, M.D. as Chief Medical Officer
Date:3/30/2011

Jay Barth will lead all clinical development programs for ataluren, an investigational new drug for the treatment of nonsense mutation genetic disorders.  Ataluren is currently being investigated for use in Duchenne and Becker muscular dystrophy, cystic fibrosis, hemophilia and methylmalonic acidemia due to a nonsense mutation.  Dr. Barth received his undergraduate degree from Columbia University and his medical degree from the University of Pennsylvania School of Medicine.  He completed a residency in Pediatrics at the Columbia-Presbyterian Medical Center and a fellowship in Pediatric Gastroenterology, Liver disease and Nutrition at the New England Medical Center.  In his previous role at Merck, Dr. Barth served as Executive Director of Clinical Development and was responsible for global clinical development programs in respiratory, supportive oncology and gastroenterology.  

"We are excited to welcome Dr. Spiegel as a member of our senior management team.  Bob's extensive clinical development experience, especially his track record in leading discussions with regulatory authorities, will be invaluable as we move ataluren toward regulatory filings," stated Dr. Stuart Peltz, President and CEO of PTC Therapeutics.  "Jay has been a key contributor to the successful execution of our ataluren development plan since 2009 and the expansion of his role further supports advancement of our development efforts with ataluren."

About PTC Therapeutics, Inc.  

PTC is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered small-molecule drugs that target post-transcriptional control processes.  Post-transcriptional control processes regulate the rate and timing of protein production and are of central importance to proper cellular function.  PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare genetic disorders,
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... July 30, 2015 PTC Therapeutics, Inc. (NASDAQ: ... reported financial results for the second quarter ending June ... many fronts across the organization.  We are excited to ... dystrophy clinical trial ever conducted with topline results expected ... Chief Executive Officer, PTC Therapeutics, Inc. "Translarna is now ...
(Date:7/30/2015)... July 30, 2015  Cleveland Clinic President Wael ... address last month that industry is compelled to adopt ... gain the efficiencies—and develop the transformational innovations -- required ... comments were preceded by Doug Kohrs , past ... moderator, who stressed that industry must add "episode of ...
(Date:7/30/2015)... VALLEY COTTAGE, New York , July 30, 2015 ... the release of its latest report titled, "Continuous Glucose ... 2015 - 2020". According to the report, the global ... 402.0 Mn in 2014 and is expected to reach ... 12.1% during the forecast period, 2015 to 2020. ...
Breaking Medicine Technology:PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10Orthopaedic Surgery Reimbursement Shifts to Episode of Care 2Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 2Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 3Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 4
... N.Y., June 23 A landmark study has ... failure or death in patients with heart disease ... with defibrillator (CRT-D) versus patients who received only ... , MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with ...
... LAUSANNE, Switzerland, June 23 Debiopharm Group,(Debiopharm), a ... the development of prescription drugs that target unmet medical,needs, ... Moapar(R),and Salvapar(R)), was launched in Germany in May 2009, ... also launched on a preliminary basis in,Belgium. The effective ...
Cached Medicine Technology:New Therapy Found to Prevent Heart Failure 2Salvacyl(R), Developed by Debiopharm, is Launched in two European Countries 2
(Date:7/31/2015)... ... July 31, 2015 , ... ... logic applies when purchasing disability insurance, where price is an important factor to ... with a leading insurance carrier, offers the Preferred Producer Multi-Life Discount program, where ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... ... apnea (OSA) and the growing number of individuals who remain undiagnosed, treatment options ... continue to shy away from traditional CPAP therapy due to its overall lack ...
(Date:7/30/2015)... ... July 30, 2015 , ... Dale Sky Jones, Executive Chancellor ... speak at the International Cannabis Professionals Expo held at the Caribe Royal All Suites ... International Cannabis Professionals Expo is the largest medical cannabis expo in the country ...
(Date:7/30/2015)... Providenciales, Turks & Caicos Islands, BWI (PRWEB) , ... July 31, 2015 , ... The ... special offer for fall, 2015. Guests who stay at the Venetian will save 40% ... , The fall months are always quiet in the Turks & Caicos, providing a ...
(Date:7/30/2015)... ... , ... Committed to helping the next generation succeed - Mercy College is ... the College’s “My Brother’s Keeper Scholarship.” The President’s signature initiative issues a call to ... support they need to think more broadly about their future. Building on what works ...
Breaking Medicine News(10 mins):Health News:Secura Consultants Gives Advisers Competitive New Edge with Multi-Life Discount Program 2Health News:Oravan Sleep Apnea Device Gains Traction in Sleep Industry 2Health News:Finally…First Ever Professional Training Event for Doctors and Nurses Wanting to Offer Medical Marijuana Recommendations to Patients 2Health News:Finally…First Ever Professional Training Event for Doctors and Nurses Wanting to Offer Medical Marijuana Recommendations to Patients 3Health News:Finally…First Ever Professional Training Event for Doctors and Nurses Wanting to Offer Medical Marijuana Recommendations to Patients 4Health News:Finally…First Ever Professional Training Event for Doctors and Nurses Wanting to Offer Medical Marijuana Recommendations to Patients 5Health News:The Venetian on Grace Bay in Turks & Caicos Islands Offers 40% Savings This Fall. 2Health News:Mercy College a “My Brother’s Keeper” Community 2Health News:Mercy College a “My Brother’s Keeper” Community 3
... ... Mr. Ohad Goren will function as Pollogen,s CEO. Pollogen recently launched its latest technology- ... action - fat reduction. , ... Tel-Aviv, Israel (PRWEB) April 19, 2010 -- Pollogen Ltd , a ...
... ... accumulated medical records knowledge to offer a full Electronic Medical Records (EMR) data conversion ... ... in healthcare connectivity solutions, now offers a full range of EMR to EMR Data ...
... those who get something lodged in their throat die , ... young children who choke after swallowing a foreign object is ... real, the latest research indicates. , "In such cases, the ... K. Shah, a pediatric otolaryngologist with the Children,s National Medical ...
... first study of vitamin K and Non-Hodgkin lymphoma ... found that people who have higher intakes of vitamin K ... lymphoma. Non-Hodgkin Lymphoma is a cancer of the immune ... United States. At the 101st Annual Meeting ...
... SAN MARCOS, TXStudents, perceptions of their overall experience on ... accomplishments, but research has also found a solid relationship ... perceptions of quality of life. Are campus green spaces ... undergrads? A new study investigating this question revealed some ...
... screening, diagnosis , MONDAY, April 19 (HealthDay News) -- Researchers ... tests could be a sign that patients are at higher ... that in blacks, a common germ boosts the risk of ... often become cancerous. , Both studies are slated to be ...
Cached Medicine News:Health News:Pollogen Ltd. Names Ohad Goren Chief Executive Officer 2Health News:Pollogen Ltd. Names Ohad Goren Chief Executive Officer 3Health News:ELLKAY Launches Electronic Medical Records (EMR) Conversion Division to Healthcare Industry 2Health News:ELLKAY Launches Electronic Medical Records (EMR) Conversion Division to Healthcare Industry 3Health News:Fatal Choking a Real Risk Among Toddlers 2Health News:Fatal Choking a Real Risk Among Toddlers 3Health News:Vitamin K may protect against developing non-Hodgkin's lymphoma, say Mayo Clinic researchers 2Health News:Vitamin K may protect against developing non-Hodgkin's lymphoma, say Mayo Clinic researchers 3Health News:Campus green space more important for undergrads 2Health News:New Risk Factors for Colon Cancer Studied 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: